Literature DB >> 19270192

Sex differences and central protective effect of 17beta-estradiol in the development of aldosterone/NaCl-induced hypertension.

Baojian Xue1, Daniel Badaue-Passos, Fang Guo, Celso E Gomez-Sanchez, Meredith Hay, Alan Kim Johnson.   

Abstract

The present study tested the hypotheses that male and female rats respond differently to subcutaneous infusions of aldosterone (Aldo; 1.8 microg.kg(-1).h(-1), 1% NaCl to drink; 28 days) and that central estrogen plays a protective role against the development of hypertension. In rats with blood pressure (BP) and heart rate (HR) measured by Data Sciences International telemetry, chronic Aldo/NaCl treatment induced a greater increase in BP in males (Delta25.4 +/- 2.4 mmHg) than in females (Delta7.1 +/- 2.2 mmHg). Gonadectomy augmented Aldo/NaCl-induced hypertension in females (Delta18.2 +/- 2.0 mmHg) but had no effect in males (Delta23.1 +/- 2.9 mmHg). Immunohistochemistry for Fra-like activity was higher in the paraventricular nucleus of intact males, castrated males, and ovariectomized (OVX) females compared with intact females after 28 days of Aldo/NaCl treatment. In intact males, central 17beta-estradiol (E(2)) inhibited the Aldo/NaCl increase in BP (Delta10.5 +/- 0.8) compared with that in central vehicle plus systemic Aldo/NaCl (Delta26.1 +/- 2.5 mmHg) rats. Combined administration of E(2) and estrogen receptor antagonist ICI182780 (ICI) blocked the protective effect of E(2) (Delta23.2 +/- 2.4 mmHg). In intact females central, but not peripheral, infusions of ICI augmented the Aldo/NaCl (Delta20.4 +/- 1.8 mmHg) BP increase. Finally, ganglionic blockade after Aldo infusions resulted in a smaller reduction in BP in intact females (-23.9 +/- 2.5 mmHg) and in central estrogen-treated males (-30.2 +/- 1.0 mmHg) compared with other groups (intact males, -39.3 +/- 3.4; castrated males, -41.8 +/- 1.9; intact males with central E(2) + ICI, -42.3 +/- 2.1; OVX females, -40.3 +/- 3.3; and intact females with central ICI, -39.1 +/- 1.3 mmHg). Chronic Aldo infusion produced increases in NaCl intake and decreases in HR that were both similar in all groups. Taken together, the results indicate that central estrogen plays a protective role in the development of Aldo/NaCl-induced hypertension and that this may result from reduced sympathetic outflow.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19270192      PMCID: PMC2685359          DOI: 10.1152/ajpheart.01255.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  47 in total

1.  Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension.

Authors:  William B White; Vladimir Hanes; Vijay Chauhan; Bertram Pitt
Journal:  Hypertension       Date:  2006-06-26       Impact factor: 10.190

2.  Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance.

Authors:  M Stowasser; A W Bachmann; P R Huggard; T R Rossetti; R D Gordon
Journal:  J Clin Endocrinol Metab       Date:  2000-06       Impact factor: 5.958

Review 3.  Aldosterone as a cardiovascular risk hormone.

Authors:  Takanobu Yoshimoto; Yukio Hirata
Journal:  Endocr J       Date:  2007-04-03       Impact factor: 2.349

4.  Effect of subfornical organ lesion on the development of mineralocorticoid-salt hypertension.

Authors:  John W Osborn; Frederic Jacob; Michael Hendel; John P Collister; Leah Clark; Pilar Ariza Guzman
Journal:  Brain Res       Date:  2006-07-21       Impact factor: 3.252

5.  11beta-hydroxysteroid dehydrogenase type 2 activity in hypothalamic paraventricular nucleus modulates sympathetic excitation.

Authors:  Zhi-Hua Zhang; Yu-Ming Kang; Yang Yu; Shun-Guang Wei; Thomas J Schmidt; Alan Kim Johnson; Robert B Felder
Journal:  Hypertension       Date:  2006-05-22       Impact factor: 10.190

6.  Estrogen in the paraventricular nucleus attenuates L-glutamate-induced increases in mean arterial pressure through estrogen receptor beta and NO.

Authors:  Sarah Gingerich; Teresa L Krukoff
Journal:  Hypertension       Date:  2006-10-30       Impact factor: 10.190

7.  Afferent renal inputs to paraventricular nucleus vasopressin and oxytocin neurosecretory neurons.

Authors:  J Ciriello
Journal:  Am J Physiol       Date:  1998-12

8.  Sex difference in pressor responsiveness to vasopressin and baroreflex function in DOC-salt hypertensive rats.

Authors:  Y Ouchi; L Share; J T Crofton; K Iitake; D P Brooks
Journal:  J Hypertens       Date:  1988-05       Impact factor: 4.844

9.  Ligand-dependent activation of ER{beta} lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats.

Authors:  Virginija Jazbutyte; Paula Anahi Arias-Loza; Kai Hu; Julian Widder; Vijayakumar Govindaraj; Christine von Poser-Klein; Johann Bauersachs; Karl-Heinrich Fritzemeier; Christa Hegele-Hartung; Ludwig Neyses; Georg Ertl; Theo Pelzer
Journal:  Cardiovasc Res       Date:  2007-12-04       Impact factor: 10.787

Review 10.  The new biology of aldosterone.

Authors:  John M C Connell; Eleanor Davies
Journal:  J Endocrinol       Date:  2005-07       Impact factor: 4.286

View more
  34 in total

1.  Effect of intracerebroventricular benzamil on cardiovascular and central autonomic responses to DOCA-salt treatment.

Authors:  Joanna M Abrams; William C Engeland; John W Osborn
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-10-06       Impact factor: 3.619

2.  Age-related changes in thirst, salt appetite, and arterial blood pressure in response to aldosterone-dexamethasone combination in rats.

Authors:  Robert L Thunhorst; Baojian Xue; Terry G Beltz; Alan Kim Johnson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-04-01       Impact factor: 3.619

3.  Estrogen regulation of the brain renin-angiotensin system in protection against angiotensin II-induced sensitization of hypertension.

Authors:  Baojian Xue; Zhongming Zhang; Terry G Beltz; Fang Guo; Meredith Hay; Alan Kim Johnson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-05-23       Impact factor: 4.733

4.  Perinatal iron deficiency and a high salt diet cause long-term kidney mitochondrial dysfunction and oxidative stress.

Authors:  Andrew G Woodman; Richard Mah; Danae L Keddie; Ronan M N Noble; Claudia D Holody; Sareh Panahi; Ferrante S Gragasin; Helene Lemieux; Stephane L Bourque
Journal:  Cardiovasc Res       Date:  2020-01-01       Impact factor: 10.787

Review 5.  Sex differences in vascular physiology and pathophysiology: estrogen and androgen signaling in health and disease.

Authors:  Austin C Boese; Seong C Kim; Ke-Jie Yin; Jean-Pyo Lee; Milton H Hamblin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

Review 6.  Sex-steroid-dependent plasticity of brain-stem autonomic circuits.

Authors:  Erica L Littlejohn; Stephanie Fedorchak; Carie R Boychuk
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-06-03       Impact factor: 3.619

Review 7.  Yes! Sex matters: sex, the brain and blood pressure.

Authors:  Meredith Hay; Baojian Xue; Alan Kim Johnson
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

8.  Estrogen metabolism by cytochrome P450 1B1 modulates the hypertensive effect of angiotensin II in female mice.

Authors:  Brett L Jennings; L Watson George; Ajeeth K Pingili; Nayaab S Khan; Anne M Estes; Xiao R Fang; Frank J Gonzalez; Kafait U Malik
Journal:  Hypertension       Date:  2014-04-28       Impact factor: 10.190

Review 9.  Sex-specific immune modulation of primary hypertension.

Authors:  Kathryn Sandberg; Hong Ji; Meredith Hay
Journal:  Cell Immunol       Date:  2014-12-08       Impact factor: 4.868

10.  Estrogen receptor-β in the paraventricular nucleus and rostroventrolateral medulla plays an essential protective role in aldosterone/salt-induced hypertension in female rats.

Authors:  Baojian Xue; Zhongming Zhang; Terry G Beltz; Ralph F Johnson; Fang Guo; Meredith Hay; Alan Kim Johnson
Journal:  Hypertension       Date:  2013-04-22       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.